In short
It’s only a week since we covered a Covalon news item, with the announcement of FDA approval of its IV Clear™ antimicrobial silicone film for use on semi-permanent vascular access devices. Now the company is further announcing its presence by pitching up with its new and advanced SilverCoat™ Antimicrobial Silicone Foley Catheter at the American Urological Association 2012 Annual Meeting (“AUA”) in Atlanta, Georgia which is taking place right now.
Background
Urinary tract infections have been identified by the United States Center for Disease Control as the most common type of healthcare associated infection, of which 75% are associated with a urinary catheter, often referred to as CAUTIs. The Centers for MediCare and Medicaid Services are no longer reimbursing medical institutions for the treatment of CAUTIs.
Now, unbelievably in its 107th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine.
Covalon will also be showcasing its advanced wound and aforementioned antimicrobial silicone adhesive technology. These exciting new products will be available for license or distribution, following regulatory clearance to the company’s growing domestic and international distribution channels and to medical product companies who are looking to license breakthrough new products.
Company comments
“We are looking forward to presenting our SilverCoat™ Antimicrobial Silicone Foley Catheter, with its lubricious and antimicrobial coating at the AUA” said Brian Pedlar, Covalon’s Chief Executive Officer. “We have demonstrated that our antimicrobial coating outperforms market-leading silver coated Foley catheters in killing the bacteria most commonly associated with urinary tract infections. The AUA provides Covalon with a great opportunity to showcase our urological care products to an international audience, including close to three hundred leading manufacturers, wholesalers and distributors.”
Source: Covalon Technologies Ltd.
published: May 23, 2012 in: Launches / Withdrawals, Urology